← All trials
NCT04530422
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2020
- Primary completion
- Jul 8, 2020
- Completion date
- Jul 23, 2020
- First posted
- Aug 28, 2020
- Last posted
- Aug 28, 2020
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Almaza Military Fever HospitalLead sponsor
- Almaza Military Fever HospitalReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.